- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-Q Quarterly report
- 2.4 Exhibit 2.4
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- Download Excel data file
- View Excel data file
Ex. 32.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the filing of the quarterly report on Form 10-Q for the quarter ended March 31, 2021 (the “Report”) by Aytu BioPharma, Inc. (the “Company”), each of the undersigned hereby certifies that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 17, 2021 |
|
| |
|
|
|
|
|
|
|
|
| By: | /s/ Joshua R. Disbrow |
|
|
| Joshua R. Disbrow |
|
|
| Chief Executive Officer (Principal Executive Officer) |
|
Date: May 17, 2021 |
|
| |
|
|
|
|
|
|
|
|
| By: | /s/ Richard Eisenstadt |
|
|
| Richard Eisenstadt |
|
|
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
|